Remdesivir and COVID-19.
Matthew J Glaus,Serena Von Ruden +1 more
About:
This article is published in The Lancet.The article was published on 2020-10-03 and is currently open access. It has received 10 citations till now. The article focuses on the topics: Betacoronavirus & Pneumonia.read more
Citations
More filters
Journal ArticleDOI
Melatonin effects on sleep quality and outcomes of COVID-19 patients: An open-label, randomized, controlled trial.
Seyed Abbas Mousavi,Keyvan Heydari,Hossein Mehravaran,Majid Saeedi,Reza Alizadeh-Navaei,Akbar Hedayatizadeh-Omran,Amir Shamshirian +6 more
TL;DR: This clinical trial study showed that the combination of oral melatonin tablets and standard treatment could substantially improve sleep quality and blood oxygen saturation in hospitalized COVID‐19 patients.
Journal ArticleDOI
Higher entropy observed in SARS-CoV-2 genomes from the first COVID-19 wave in Pakistan.
Najia Karim Ghanchi,Asghar Nasir,Kiran Iqbal Masood,Syed Hani Abidi,Syed Faisal Mahmood,Akbar Kanji,Safina Abdul Razzak,Waqasuddin Khan,Saba Shahid,Maliha Yameen,Ali Raza,Javaria Ashraf,Zeeshan Ansar,Mohammad Buksh Dharejo,Nazneen Islam,Zahra Hasan,Rumina Hasan,Rumina Hasan +17 more
TL;DR: In this article, the authors investigated the genome diversity of SARS-CoV-2 associated with the early COVID-19 period to investigate evolution of the virus in Pakistan.
Journal ArticleDOI
Inhibitory efficacy of RNA virus drugs against SARS-CoV-2 proteins: An extensive study
Manab Mandal,Swapan Kumar Chowdhury,Abdul Ashik Khan,Nabajyoti Baildya,Tanmoy Dutta,Debabrata Misra,Narendra Nath Ghosh +6 more
TL;DR: In this article, the authors made a comprehensive analysis of inhibitory efficacy of 16 RNA virus drugs against RdRp, Mpro and PLpro proteins of SARS-CoV-2.
Journal ArticleDOI
Ontological modeling and analysis of experimentally or clinically verified drugs against coronavirus infection.
Yingtong Liu,Junguk Hur,Wallace K.B. Chan,Zhigang Wang,Jiangan Xie,Duxin Sun,Samuel K. Handelman,Jonathan Z. Sexton,Hong Yu,Yongqun He +9 more
TL;DR: In this paper, the authors used the Coronavirus Infectious Disease Ontology (CIDO) as an ontological platform to represent the anti-coronaviral drugs, chemical compounds, drug targets, biological processes, viruses, and the relations among these entities.
Journal ArticleDOI
Current and New Drugs for COVID-19 Treatment and Its Effects on the Liver
TL;DR: This review aims to provide the latest insights on various drugs being used in the treatment of COVID-19 and their effects on the liver.
References
More filters
Journal ArticleDOI
Clinical Characteristics of Coronavirus Disease 2019 in China.
Wei-jie Guan,Zhengyi Ni,Yu Hu,Wenhua Liang,Chun-Quan Ou,Jianxing He,Lei Liu,Hong Shan,Chunliang Lei,David S.C. Hui,Bin Du,Lanjuan Li,Guang Zeng,Kowk-Yung Yuen,Ruchong Chen,Chun-Li Tang,Tao Wang,Ping-Yan Chen,Jie Xiang,Shiyue Li,Jinlin Wang,Zi-jing Liang,Yi-xiang Peng,Li Wei,Yong Liu,Ya-hua Hu,Peng Peng,Jian-ming Wang,Ji-yang Liu,Zhong Chen,Gang Li,Zhi-jian Zheng,Shao-qin Qiu,Jie Luo,Chang-jiang Ye,Shao-yong Zhu,Nanshan Zhong +36 more
TL;DR: During the first 2 months of the current outbreak, Covid-19 spread rapidly throughout China and caused varying degrees of illness, and patients often presented without fever, and many did not have abnormal radiologic findings.
Journal ArticleDOI
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Yeming Wang,Yeming Wang,Dingyu Zhang,Guanhua Du,Ronghui Du,Jianping Zhao,Yang Jin,Shouzhi Fu,Ling Gao,Zhenshun Cheng,Qiaofa Lu,Yi Hu,Guangwei Luo,Ke Wang,Yang Lu,Huadong Li,Shuzhen Wang,Shunan Ruan,Chengqing Yang,Chunlin Mei,Yi Wang,Dan Ding,Feng Wu,Xin Tang,Xianzhi Ye,Yingchun Ye,Bing Liu,Jie Yang,Wen Yin,Aili Wang,Guohui Fan,Fei Zhou,Zhibo Liu,Xiaoying Gu,Jiuyang Xu,Lianhan Shang,Lianhan Shang,Yi Zhang,Lianjun Cao,Guo Tingting,Yan Wan,Hong Qin,Yushen Jiang,Thomas Jaki,Thomas Jaki,Frederick G. Hayden,Peter Horby,Bin Cao,Chen Wang +48 more
TL;DR: In this study of adult patients admitted to hospital for severe COVID-19, remdesivir was not associated with statistically significant clinical benefits, however, the numerical reduction in time to clinical improvement in those treated earlier requires confirmation in larger studies.
Journal ArticleDOI
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Timothy P. Sheahan,Amy C. Sims,Rachel L. Graham,Vineet D. Menachery,Lisa E. Gralinski,James Brett Case,Sarah R. Leist,Krzysztof Pyrc,Joy Y. Feng,Iva Trantcheva,Roy Bannister,Yeojin Park,Darius Babusis,Michael O. Clarke,Richard L. Mackman,Jamie E. Spahn,Christopher A. Palmiotti,Dustin Siegel,Adrian S. Ray,Tomas Cihlar,Robert Jordan,Mark R. Denison,Ralph S. Baric +22 more
TL;DR: Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses in vitro and in vivo and may prove effective against endemic MERS-CoV in the Middle East, circulating human CoV, and, possibly most importantly, emerging CoV of the future.
Journal ArticleDOI
Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease
Maria L. Agostini,Erica L. Andres,Amy C. Sims,Rachel L. Graham,Timothy P. Sheahan,Xiaotao Lu,Everett Clinton Smith,Everett Clinton Smith,James Brett Case,Joy Y. Feng,Robert Jordan,Adrian S. Ray,Tomas Cihlar,Dustin Siegel,Richard L. Mackman,Michael O'neil Hanrahan Clarke,Ralph S. Baric,Mark R. Denison +17 more
TL;DR: It is shown that GS-5734 inhibits murine hepatitis virus (MHV) with similar 50% effective concentration values (EC50) as SARS-CoV and Middle East respiratory syndrome coronavirus (MERS- coV) and that resistance can be overcome with increased, nontoxic concentrations of GS- 5734, further supporting the development of GS -5734 as a broad-spectrum therapeutic to protect against contemporary and emerging CoVs.
Journal ArticleDOI
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
Emmie de Wit,Friederike Feldmann,Jacqueline Cronin,Robert Jordan,Atsushi Okumura,Tina Thomas,Dana P. Scott,Tomas Cihlar,Heinz Feldmann +8 more
TL;DR: The data show that remdesivir is a promising antiviral treatment against MERS that could be considered for implementation in clinical trials, and may also have utility for related coronaviruses such as the novel coronavirus 2019-nCoV emerging from Wuhan, China.